Regeneration therapy for diabetes mellitus

Expert Opinion on Biological Therapy

Volumn 3, Issue 3, 2003, Pages 425-433

  Yamaoka, Takashi ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

ES cells; Field theory gene therapy; Immunoisolation; In situ regeneration therapy; In vivo regeneration therapy; Islet transplantation; Transdifferentiation

Indexed keywords

CALCINEURIN INHIBITOR; CD40 LIGAND MONOCLONAL ANTIBODY; CYCLIN DEPENDENT KINASE 4; CYCLOSPORIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACLIZUMAB; GROWTH HORMONE; HYBRID PROTEIN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INSULIN; INTERLEUKIN 2 RECEPTOR ANTIBODY; MONOCLONAL ANTIBODY CD3; PLATELET DERIVED GROWTH FACTOR; PROLACTIN; PROTEIN KINASE B; RAPAMYCIN; SOMATOMEDIN B; SOMATOMEDIN C; STEROID; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADOPTIVE IMMUNOTHERAPY; CELL PROLIFERATION; CELL REGENERATION; CELL TRANSPLANTATION; DRUG DELIVERY SYSTEM; GENE THERAPY; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; LOW DRUG DOSE; NEPHROTOXICITY; PANCREAS CELL; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; PROTEIN FUNCTION; REVIEW; STEM CELL;

ANIMALS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; GENE THERAPY; GENETIC ENGINEERING; HUMANS; REGENERATION; STEM CELL TRANSPLANTATION;

EID: 0038540683     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/eobt.3.3.425.21177     Document Type: Review

References (53)

1. LUGAGNE PM, REACH G, HOURY S, PEUCHEMAURE M, ROUCHETTE J, HUGUIER M: Portal versus peripheral venous drainage in segmental pancreatic transplantation in diabetic rats. Transplantation (1989) 47:420-423.
2. LUCK R, KLEMPNAUER J, EHLERDING G, KUHN K: Significance of portal venous drainage after whole-organ pancreas transplantation for endocrine graft function and prevention of diabetic nephropathy. Transplantation (1990) 50:394-398.
3. SHOKOUH-AMIRI MH, RAHIMI-SABER S, ANDERSEN HO, JENSEN SL: Pancreas autotransplantation in pig with systemic or portal venous drainage. Effect on the endocrine pancreatic function after transplantation. Transplantation (1996) 61:1004-1009.
4. PHILOSOPHE B, FARNEY AC, SCHWEITZER EJ et al: Superiority of portal venous drainage over systemic venous drainage in pancreas transplantation: a retrospective study. Ann. Surg. (2001) 234:689-696.
5. GRAY DWR: An overview of the immune system with specific reference to membrane encapsulation and islet transplantation. Ann. NY Acad. Sci. (2001) 944:226-239. Problems of immunoisolation techniques are discussed.
6. ORIVE G, HERNANDEZ RM, GASCON AR et al.: Cell encapsulation: promise and progress. Nat. Med. (2003) 9:104-107.
7. WONG FS, KARTTUNEN J, DUMONT C et al.: Identification of MHC class I-restricted autoantigen in Type 1 diabetes by screening an organ-specific cDNA library. Nat. Med. (1999) 5:1026-1031.
8. LAMMERT E, CLEAVER O, MELTON D: Induction of pancreatic differentiation by signals from blood vessels. Science (2001) 294:564-567.
9. BERNEY T, BUHLER L, CAULFIELD A et al.: Transplantation of islets of Langerhans: new developments. Swiss Med. Wkly. (2001) 132:671-680. An overview of islet transplantation with 86 references.
10. SHAPIRO AM, LAKEY JR, RYAN EA et al.: Islet transplantation in seven patients with Type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N. Engl. J. Med. (2000) 343:230-238. A standard protocol of modern islet transplantation, referred to as the 'Edmonton Protocol'.
11. BURRIDGE PW, SHAPIRO AMJ, RYAN EA, LAKEY JRT: Future trends in clinical islet transplantation. Transplant. Proc. (2002) 34:3347-3348.
12. SHAPIRO AM, SUAREZ-PINZON WL, POWER R, RABINOVITCH A: Combination therapy with low dose sirolimus and tacrolimus is synergistic in preventing spontaneous and recurrent autoimmune diabetes in non-obese diabetic mice. Diabetologia (2002) 45:224-230.
13. WEKERLE T, KURTZ J, ITO H et al.: Allogenic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. Nat. Med. (2000) 6:464-469. Long-term chimaerism and donor-specific tolerance was achieved with high-dose bone marrow transplantation and costimulatory blockade of T lymphocytes.
14. ADLER SH, TURKA LA: Immunotherapy as a means to induce transplantation tolerance. Curr. Opin. Immunol. (2002) 14:660-665.
15. KORBUTT GS, ELLIOTT JF, RAJOTTE RV: Cotransplantation of allogeneic islets with allogeneneic testicular cell aggregates allows long-term graft survival without systemic immunosuppression. Diabetes (1997) 46:317-322.
16. LAU HT, YU M, FONTANA A, STOECHERT CJ JR: Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science (1996) 273:109-112.
17. KANG SM, SCHNEIDER DB, LIN Z et al.: Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat. Med (1997) 3:738-743.
18. NIEMANN H: Current status and perspectives for the generation of transgenic pigs for xenotransplantation. Ann. Transplant. (2001) 6:3-9.
19. VAN DER LAAN LJ, LOCKEY C, GRIFFETH BC et al.: Infection by porcine endogenous retrovirus after islet xenotransplantation in SCID mice. Nature (2000) 407:90-94.
20. HENEINE W, TIBELL A, SWITZER WM et al.: No evidence of infection with porcine endogenous retrovirus in recipients of porcine islet-cell xenografts. Lancet (1998) 352:695-699.
21. PARADIS K, LANGFORD G, LONG Z et al.: Search for cross-species transmission of porcine endogenous retrovirus in patients treated with living pig tissue. The XEN 111 Study Group. Science (1999) 285:1236-1241.
22. BEATTIE GM, MONTGOMERY AM, LOPEZ AD et al.: A novel approach to increase human islet cell mass while preserving β-cell function. Diabetes (2002) 51:3435-3439.
23. RAMIYA VK, MARAIST M, ARFORS KE, SCHATZ DA, PECK AB, CORNELIUS JG: Reversal of insulin-dependent diabetes using islets generated in vitro from pancreatic stem cells. Nat. Med. (2000) 6:278-282. Mouse pancreatic ductal epithelial cells were cultured and a great number of islets were produced fiom these cultured cells.
24. BONNER-WEIR S, TANEJA M, WEIR GC et al.: In vitro cultivation of human islets from expanded ductal tissue. Proc. Acad. Natl. Sci. USA (2000) 97:7999-8004. Islet-like cell clusters were produced from cultured human pancreatic ductal cells.
25. ZULEWSKI H, ABRAHAM EJ, GERLACH MJ et al.: Multipotential nestin-positive stem cells isolated from adult pancreatic islets differentiate ex vivo into pancreatic endocrine, exocrine, and hepatic phenotypes. Diabetes (2000) 50:521-533. It has been debated whether nestin-positive pancreatic cells are real stem cells.
26. LUMELSKY N, BLONDEL O, LAENG P, VELASCO I, RAVIN R, MCKAY R: Differentiation of embryonic stem cells to insulin-secreting structures similar to pancreatic islets. Science (2001) 292:1389-1394.
27. SORIA B, ROCHE E, BERNA G, LEON-QUINTO T, REIG JA, MARTIN F: Insulin-secreting cells derived from embryonic stem cells normalize glycemia in streptozotocin-induced diabetic mice. Diabetes (2000) 49:157-162.
28. ASSADY S, MAOR G, AMIT M, ITSKOVITZ-ELDOR J, SKORECKI KL, TZUKERMAN M: Insulin production by human embryonic stem cells. Diabetes (2001) 50:1691-1697.
29. YANG L, LI S, HATCH H et al.: In vitro trans-differentiation of adult hepatic stem cells into pancreatic endocrine hormone-producing cells. Proc. Natl. Acad. Sci. USA (2002) 99:8078-8083.
30. RAJAGOPAL J, ANDERSON WJ, KUME S, MARTINEZ OI, MELTON DA: Insulin staining of ES cell progeny from insulin uptake. Science (2003) 299:363.
31. KEYMEULEN B, KORBUTT G, DE PAEPE M, GORUS F, KLOPPEL G, PIPELEERS DG: Long-term metabolic control by rat islet grafts depends on the composition of the implant. Diabetes (1996) 45:1814-1821.
32. YAMAOKA T: Gene therapy for diabetes mellitus. Curr. Mol. Med. (2001) 1:325-337.
33. LEE HC, KIM SJ, KIM KS, SHIN HC, YOON JW: Remission in models of Type 1 diabetes by gene therapy using a single-chain insulin analogue. Nature (2000) 408:483-488.
34. VALERA A, FILLAT C, COSTA C et al.: Regulated expression of human insulin in the liver of transgenic mice corrects diabetic alteration. FASEB J. (1994) 8:440-447.
35. GROS L, MONTOLIU L, RIU E, LEBRIGAND L, BOSCH F: Regulated production of mature insulin by non-β-cells. Hum. Gene Ther. (1997) 8:2249-2259.
36. JIANG Y, JAHAGIRDAR BN, REINHARDT RL et al.: Pluripotency of mesenchymal stem cells derived from adult marrow. Nature (2002) 418:41-49.
37. TERADA N, HAMAZAKI T, OKA M et al.: Bone marrow cells adopt the phenotype of other cells by spontaneous cell fusion. Nature (2002) 416:542-545.
38. YING QL, NICHOLS J, EVANS EP, SMITH AG: Changing potency by spontaneous fusion. Nature (2002) 416:545-548.
39. FERBER S, HALKIN A, COHEN H et al.: Pancreatic and duodenal homeobox gene 1 induces expression of insulin genes in liver and ameliorates streptozotocin-induced hyperglycemia. Nat. Med. (2000) 6:568-572. Transdifferentiation of hepatocytes into insulin-producing cells by gene transfer. Combination of regeneration therapy and gene therapy.
40. TANIGUCHI H, YAMATO E, TASHIRO F, IKEGAMI H, OGIHARA T, MIYAZAKI J: β-cell neogenesis induced by adenovirus-mediated gene delivery of transcription factor pdx-1 into mouse pancreas. Gene Ther. (2003) 10:15-23.
41. PARSONS JA, HARTFEL MA, HEGRE OD, MCEVOY RC: Effect of MtTW15 mammosomatotropic tumors on pancreatic islet hormones. Diabetes (1983) 32:67-74.
42. SORENSON RL, PARSONS JA: Insulin secretion in mammosomatotropic tumor-bearing and pregnant rats. A role for lactogens. Diabetes (1985) 34:337-341.
43. PARSONS JA, BARTKE A, SORENSON RL: Number and size of islets of Langerhans in pregnant, human growth hormone-expressing transgenic, and pituitary dwarf mice: effect of lactogenic hormones. Endocrinology (1995) 136:2013-2021.
44. VASAVADA RC, CAVALIERE C, D'ERCOLE AJ et al.: Overexpression of parathyroid hormone-related protein in the pancreatic islets of transgenic mice causes islet hyperplasia, hyperinsulinemia, and hypoglycemia. J. Biol. Chem. (1996) 271:1200-1208.
45. GARCIA-OCANA A, TAKANE KK, SYED MA, PHILBRICK WM, VASABADA RC, STEWART AR: Hepatocyte growth factor overexpression in the islet of transgenic mice increases beta cell proliferation, enhances islet mass, and induces mild hypoglycemia. J. Biol. Chem. (2000) 275:1226-1232.
46. WITHERS DJ, GUTIERREZ JS, TOWERY H et al.: Disruption of IRS-2 causes Type 2 diabetes in mice. Nature (1998) 391:900-904. The β-cell mass of IRS-2-deficient mice was reduced by 40% compared with that of wild type mice.
47. CHEN WS, XU PZ, GOTTLOB K et al.: Growth retardation and increased apoptosis in mice with homozygous disruption of the aktl gene. Genes Dev. (2001) 15:2203-2208.
48. TUTTLE RL, GILL NS, PUGH W et al.: Regulation of pancreatic β-cell growth and survival by the serine/threonine protein kinase Akt1/PKBα. Nat. Med. (2001) 7:1133-1137.
49. BERNAL-MIZRACHI E, WEN W, STAHLHUT S, WELLING CM, PERMUTT MA: Islet β cell expression of constitutively active Akt1/PKBα induces striking hypertrophy, hyperplasia, and hyperinsulinemia. J. Clin. Invest. (2001) 108:1631-1638.
50. RANE SG, DUBUS P, METTUS RV et al.: Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in β-islet cell hyperplasia. Nat. Genet. (1999) 22:44-52. The islet area was increased by 7 - 10-fold by Cdk4 activation in knock-in mice.
51. FAUSTMAN D: Reversal of established autoimmune diabetes by in situ β-cell regeneration. Ann. NY Acad. Sci. (2002) 961:40.
52. LIECHTY KW, MACKENZIE TC, SHAABAN AF et al.: Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep. Nat. Med. (2000) 6:1282-1286.
53. ORLIC D, KAJSTURA J, CHIMENTI S et al.: Bone marrow cells regenerate infarcted myocardium. Nature (2001) 410:701-705.